Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07215312

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hyperglycemia Hypoglycemia Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CIPREC, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have type 2 diabetes
  • Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
  • Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
  • Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion criteria

  • Have type 1 diabetes

Treatment and study plan

LY3938577

Drug

Administered SC

Degludec

Drug

Administered SC

Primary outcomes

  1. Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)

    Time frame: Baseline through Week 20

Secondary outcomes

  1. Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Superiority Analysis)

    Time frame: Baseline through Week 20

  2. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 20

  3. Pharmacokinetics (PK): Average Concentration of LY3938577

    Time frame: Baseline through Week 20

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 10, 2025
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.